The dorsal cell fate determination factor b-catenin and its antagonist, the ventral cell fate determination factor Xom, are expressed and distributed in a polarized fashion during early vertebrate embryogenesis. Ubiquitin-mediated proteolysis has been shown to control the abundance of both b-catenin and Xom. However, the mechanism of ubiquitin-mediated proteolysis in regulating dorsoventral patterning remains largely unclear. Our current study shows that Xom induces proteolysis of b-catenin through GSK3-mediated phosphorylation of Ser33/37 of b-catenin. Our findings reveal a novel pathway that regulates b-catenin stability, and suggest, for the first time, a critical function of ubiquitin-mediated proteolysis in balancing the integration of dorsal-ventral signals and the polarized distribution of b-catenin and Xom during dorsoventral axis formation.
The dorsal cell fate determination factor b-catenin and its antagonist, the ventral cell fate determination factor Xom, are expressed and distributed in a polarized fashion during early vertebrate embryogenesis. Ubiquitin-mediated proteolysis has been shown to control the abundance of both b-catenin and Xom. However, the mechanism of ubiquitin-mediated proteolysis in regulating dorsoventral patterning remains largely unclear. Our current study shows that Xom induces proteolysis of b-catenin through GSK3-mediated phosphorylation of Ser33/37 of b-catenin. Our findings reveal a novel pathway that regulates b-catenin stability, and suggest, for the first time, a critical function of ubiquitin-mediated proteolysis in balancing the integration of dorsal-ventral signals and the polarized distribution of b-catenin and Xom during dorsoventral axis formation.
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The molecular mechanism underlying dorsoventral axis formation is a target of extensive investigations for its broad implications in cell fate determination under physiological and pathological conditions. It has been described that dorsalization is dictated by signals from the dorsal signaling center and is antagonized by signals from the ventral signaling center [1, 2] . Ubiquitinmediated proteolysis is implicated in dorsoventral patterning with its involvement in affecting the abundance of both b-catenin of the dorsal signaling center and Xom of the ventral signaling centers [3, 4] .
b-catenin is an essential constituent of the dorsal Spemann signaling center. During early embryogenesis, b-catenin accumulates in the dorsal signaling center, transactivates the high-mobility-group box (HMG) containing transcriptional factors, the LEF/TCF factors, and drives the expression of dorsal specific genes, such as Gooscoid and Simois [5] [6] [7] [8] [9] . Mutagenesis and biochemical studies showed that b-catenin is an unstable protein whose stability is regulated by phosphorylation of its Serine33/37 residues. The GSK3 kinase complex has been identified as the b-catenin Ser33/37 kinase [10] [11] [12] . Besides its role in early embryogenesis, gain-of-function mutations of components of GSK3 kinase complex, which lead to increased stability of b-catenin, have been implicated in malignant transformation of a variety of common malignancies, such as the colorectal cancer and melanoma [13, 14] . Abbreviations 
DAPI, 4
0 ,6-diamidino-2-phenylindole; EGTA, ethylene glycol tetraacetic acid; HMG, high-mobility-group box; MMR, Marc's Modified Ringer's.
Xom is a homeobox transcriptional factor and an essential component of the ventral signaling center. Xom functions downstream of BMP4 and forms a positive feedback loop with BMP4 to re-enforce the ventral signaling and to counteract dorsal signaling effects driven by b-catenin/LEF/TCF [15] [16] [17] [18] . Previous studies showed that Xom exerts its ventralizing effect by binding to the BIE motif of dorsal-specific genes, such as goosecoid, and inhibits the expression of dorsal specific genes as a direct transcriptional repressor [19] . Xom is initially transcribed after mid-blastula transition and is expressed throughout the embryo [15, 16] . With the onset of gastrulation, Xom becomes concentrated at the ventral signaling center and is absent from the dorsal Spemann organizer [15, 16, 20] . Using a method of biochemical screening, we found that, similar to b-catenin, Xom is also an unstable protein regulated by ubiquitin-mediated proteolysis [4] . The destruction motif of Xom shares strong similarity to the destructive motif of b-catenin. Moreover, both proteins are degraded by SCF-b-TRCP E3 ligase. Interestingly, in an effort to decipher the mechanisms underlying the integration of dorsal ventral signals, we found that Xom also binds to LEF/TCF factors and activates LEF/TCF-mediated transcription [21] .
In our current studies, using a Xom-specific antibody, we found that the peak of Xom expression with the onset of gastrulation correlates with the nadir of b-catenin expression. We further discovered that Xom induces proteolysis of b-catenin in Xenopous tissue culture and embryos. Using both gain-of-function and loss-of-function approaches, we established that Xom induced the expression of GSK3 and the phosphorylation of b-catenin Ser33/37. Mutagenesis analysis showed that the C-terminal region of Xom is the critical domain required for Xom-induced expression of GSK3 and degradation of b-catenin. Taken together, our data suggest a role of Xom in regulating b-catenin stability during early embryogenesis and a critical function of ubiquitin-mediated proteolysis in balancing the dorsal-ventral signals and the polarized distribution of b-catenin and Xom during dorsoventral axis formation.
Experimental procedures

Preparation of Xenopus embryos and embryonic extracts
Xenopus embryos were obtained by in vitro fertilization. Embryos were cultured and staged according to the previously published methods [22, 23] . For a typical injection experiment, five embryos were used and embryonic extracts were obtained at indicated developmental stage essentially as described [11] . Embryonic extracts were prepared essentially as described, with some modifications [24] . Embryos of specific developmental stages were collected and dejellied. After three washes with 0.1 9 Marc's Modified Ringer's (MMR) solution, the embryos were washed once in extraction buffer (XB; 100 mM KCl, 1 mM MgCl 2 , 0.1 mM CaCl 2 , 5 mM Hepes/pH7.5, 0.2% NP-40, and protease inhibitors) with 100 mM sucrose and then packed in 1.5 mL Eppendorf tubes by spinning at 300 g for 30 s. The crude extracts were cleared by spinning at 14 000 g for 15 min, and aliquots of the staged extracts were quickly frozen in liquid nitrogen and kept in À80°C for further use.
Plasmids, mRNA, and morpholino oligos Xom and Xom deletion mutants were subcloned by the polymerase chain reaction-based technique into the pCS2 or pCS2-GFP vectors. The insertions were verified by in vitro translation and sequencing. mRNAs were prepared as described previously [4] . Xom morpholino oligo, 5 0 -
GTCATCTTGTCTGTATTAGTCCT-3
0 was obtained from Gene Tools LLC and prepared as described [25] . 
Cell culture and transfection
Confocal microscopy
A6 cells were seeded on glass chamber slides and transfected with constructs encoding GFP-Xom, GFPXomND175, GFP-XomHD110, and GFP-XomCD85. Twenty-four hours post-transfection, the cells were fixed with 2% paraformaldehyde in PBS, and counterstained by propidium iodide (PI, Sigma). After four washes in PBS for 5 min each, the slides were mounted and analyzed by confocal microscopy.
In situ chromatin binding assay
In situ chromatin binding assay was done essentially as described [26] . Cells grown on chamber slides were first washed in cold PBS. 
Pulse-chase analysis
The pulse-chase analysis was carried out essentially as described [27] . 
Small-interfering RNA
GSK3b knockdown was carried out, using a SignalSilence GSK3a/b siRNA kit (Cell Signaling, Boston, MA). The coding sequence (GUAGUACCGAGAGCAGAUGU) was chosen as the target for siRNA as described previously [28] . A6 cells, at 60% confluence, were washed with Opti-MEM I reduced serum medium (Invitrogen) and transiently transfected with SiGSK3b with Lipofectamine 2000 (Invitrogen), following the manufacturer's instructions. After 48 h, the level of endogenous GSK3b protein was assessed by western blotting.
Cellular growth assay
Cells were transfected with Lipofectamine 2000 (Invitrogen) according to the instructions of the manufacturer. Cell growth was measured by 3- 
Colony formation assay
Xenopus A6 cells were transfected with constructs encoding GFP-Xom or its deletion mutants by Lipofectamine 2000 (Invitrogen), in 100-cm 2 cell culture dishes. The cells were then collected and sorted, using a FAC G4 sort flow cytometer (BD Biosciences). These GFP-positive cells were plated in six-well plates at dilutions of 1 9 10 5 cells per well. Cells were allowed to grow for 5-10 days before staining with Crystal Violet (Sigma). All experiments were repeated at least twice, and similar results were obtained in each trial.
Cellular fractionation
Floating and attached cells were harvested from two 60-cm 2 dish by centrifugation. The cells were resuspended in homogenization buffer [0.25 molÁL À1 sucrose, 10 mmolÁL À1 HEPES (pH 7.4), and 1 mmolÁL À1 EGTA] and subjected to 40 strokes of homogenization on ice, using a 2-mL Dounce homogenizer. The homogenates were centrifuged at 1000 9 g at 4°C for 10 min to pellet the nuclei. The supernatant was subsequently centrifuged at 14 000 9 g at 4°C for 30 min to obtain cytosolic (supernatant) fractions. Pelleted nuclei was further lysed in buffer A (50 mM TrisHCl, pH7.8, 420 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 0.34 M sucrose, 10% glycerol, 1 mM Na 3 VO 4 , 10 mM NaF and b-glycerophosphate, 1 mM PMSF, and protease inhibitor cocktail) to extract nuclear proteins. Membrane proteins were isolated by Mem-PER Eukaryotic Membrane Protein Extraction Kit (Thermo Fisher Scientific, Rockford, IL), following the manufacture's instruction. Total proteins were extracted through direct lysis of cells in Buffer A.
Western blotting and antibodies
Embryonic extracts, cellular lysates, were separated by 4-20% Tris-Glycine Gel (Invitrogen, Carlsbad, CA) electrophoresis. Antibodies used include GFP (Santa Cruz Biotech, Santa Cruz, CA), Histone-1 (Ab-1, NeoMarkers, Fremont, CA), GSK3b (Sigma), phospho-b-catenin (pSer 33 / pSer 37 ) and b-catenin (Sigma), b-tubulin (Sigma), and bactin (Sigma). Xom antibody was prepared by immunization of rabbit with Xom N-terminal peptide and was affinity purified (Genmed). Appropriate horseradish peroxidase-conjugated secondary antibodies were used to detect the bound primary antibodies antigen complex with Western LightningÒ Western Blot Chemiluminescence Reagent Plus (PerkinElmer, Boston, MA).
Reverse transcription PCR and real-time PCR
Total RNA was isolated using the TRIzolÒ Reagent (Invitrogen) according to the instructions of the manufacturer. First-strand cDNA was synthesized using Superscript II reverse transcriptase (Invitrogen). Subsequently, each RT reaction mixture was subjected to PCR amplification was performed with a heat denaturation step (94°C for 60 s), an annealing step (57°C for 30 s), and an extension step (72°C for 30 s). The PCR products were size fractionated on a 2% agarose gel, and visualized under ultraviolet light. 
Statistical analysis
Results are expressed as mean AE SD. Statistical analysis was evaluated by ANOVA analysis in which multiple comparisons were performed by using the method of least significant difference. Differences were considered significant if the probability of the difference occurring by a chance less than 5% (P < 0.05).
Results
Xom expression is elevated at gastrulation during early Xenopus embryogenesis
Xom is a homeobox gene of the BMP4 signaling pathway and plays a critical role in cell fate determination during the establishment of dorsoventral axis. It has been shown that Xom forms a positive feedback loop with the BMP4 in establishing the ventral signaling center, which counteract the signals from dorsal signaling center, executed by b-catenin of the Wnt signaling pathway [16, 17] . The expression and function of Xom remains to be fully defined. Using Xom N-terminal peptide, we have raised Xom-specific antibodies and characterized the expression of Xom during early embryogenesis. Consistent with prior findings by RT-PCR examination, we found that Xom expression is elevated at the onset of gastrulation at stage 9. Xom protein level reaches its peak during gastrulation at stage 10 ( Fig. 1) . In comparison to the RT-PCR data which showed that Xom mRNA continues to rise until a much later stage [15] , we found that Xom protein level rapidly declines after stage 11. This finding is consistent with our previous findings that Xom is an unstable protein and that Xom proteolysis by the ubiquitin-mediated pathway is accelerated at the postgastrulation stage [4] . Xom and b-catenin are the two essential cell fate determination factors of the ventral and dorsal signaling center, respectively, and are distributed in a polarized fashion [15, 29] . Interestingly, in addition to the polarized distribution of Xom and b-catenin at the ventral and dorsal signaling center, we found that the peak of Xom protein level correlates with a nadir of the b-catenin protein levels at the gastrulation stage (Fig. 1 ).
Expression and nuclear targeting of Xom in Xenopus cells
To explore the potential cellular function of Xom, we have characterized the intracellular expression and distribution of Xom. As expected, Xom is expressed and targeted to nuclei in Xenopus cells ( Fig. 2A,B) . To determine the critical domains of Xom required for its nuclear localization, we made Xom deletion mutants and GFP chimera. As shown in Fig. 2B region (XomND175), the Xom mutants lacking either the homeodomain region or the C-terminal region are distributed throughout the cytoplasm of the transfected cells in the immunocytochemistry assay. To further confirm the potential involvement of the Xom homeodomain and C-terminal region in the nuclear targeting of Xom, we examined the intracellular distribution of Xom protein and its deletion mutants by subcellular fractionation. Consistent with the immunocytochemistry data, biochemical data showed that, in the transfected cells, wild-type Xom and XomND175
were concentrated in the nuclei, which were marked by Histone-H1. In comparison, XomHD and XomCD85 were distributed in both the cytoplasm and nuclear fractions, which were marked by b-actin (Fig. 2C) . To further explore the potential mechanism of the nuclear concentration of the Xom, we examined the interaction between Xom and its deletion mutants with chromatin, using an in situ chromatin binding assay. We found that while both Xom and XomND175 binds to chromatin, deletion of Xom homeodomain or C-terminal regions abrogate the interaction between Xom and GFP-Xom or GPF-tagged Xom deletion mutants were transfected A6 cells. Twenty-four hours post-transfection, the cellular proteins were extracted as described in material and methods and fractioned into nuclear and cytosolic fractions. The proteins concentration of Xom and its deletion mutants in each subcellular fraction were determined with anti-GFP antibody in subsequent western blot analysis. Histone-1 and b-actin were used as the control for loading and markers for nuclear and total proteins, respectively. Note, Xom and XomND175 is concentrated in nuclei of transfected cells, whereas XomHD and XomCD85 were distributed in both the cytoplasm and nuclear portions.
(D)
The homeodomain and C-terminal region of Xom are involved in Xom interaction with chromatin. GFP-Xom.FL or GFP-tagged Xom mutants were transfected into A6 cells. The potential interaction between Xom and its deletion mutants with chromatin were determined by in situ chromatin binding assay as previously described. Note, deletion of Xom homeodomain and C-terminal regions abrogated the interaction between Xom and chromatin.
chromatin, suggesting a potential role of these regions in Xom's interaction with chromatin (Fig. 2D) .
Xom induces b-catenin proteolysis
Xom and b-catenin are the essential cell fate determination factor of the ventral and dorsal signaling center, respectively. Our recent studies showed that Xom and b-catenin converge on the high-mobility group containing transcriptional factors, LEF/TCFs, for its integrated effects on cell fate [21] . Both Xom and b-catenin are unstable protein. The convergence of these two factors on LEF/TCFs prompted us to explore the potential interaction between these two molecules. For this purpose, plasmid encoding GFPXom was transfected into Xenopus A6 cells, as shown in Fig. 3A , with the escalation of Xom expression, we observed a corresponding decline of intracellular bcatenin level. To explore the mechanisms underlying Xom-induced decline of intracellular b-catenin level, we examine the effects of Xom on the expression of bcatenin mRNA by RT-PCR and qRT-PCR. We found that ectopic expression of Xom does not significantly reduce the expression of b-catenin (Fig. 3B) . These data suggest a potential effect of Xom on the stability of b-catenin. To prove this hypothesis, we examined bcatenin stability upon the expression of Xom, using pulse-chase assay. As shown in Fig. 3C , in comparison to vector control, b-catenin protein levels were significantly reduced upon the expression of Xom, suggesting that Xom induced proteolysis of b-catenin. In addition to the Xenopus A6 cells, we also tested and confirmed the effects of Xom on b-catenin stability in other cell types, such as human 293T cells. Taken together, the results of tissue culture experiments suggest a regulatory loop of Xom-induced proteolysis of b-catenin. To further determine whether Xom induce proteolysis of b-catenin in vivo, we overexpressed Xom in Xenopus embryos by microinjection of Xom mRNA into both blastomeres of Xenopous embryos at the two-cell stage. As shown in Fig. 3D , ectopic expression of Xom decreases b-catenin level in developing embryos but not the b-tubulin control, suggesting a potential role of Xom in regulating b-catenin protein level in vivo. In addition to the gain-of-function assay, we also explored the potential effects of Xom on b-catenin protein level by loss-of-function assay. Xom morpholino oligo developed by Sander's et al. was used to down-regulate the expression of Xom in Xenopus laevis [25] . In comparison with the gain-of-function approach, we found that the effect of Xom down-regulation on the b-catenin protein level was less obvious (Fig. 3E ).
GSK3b-mediated Xom-induced proteolysis of b-catenin
Previous investigations have established the role of GSK3b in phosphorylation of b-catenin and induction of b-catenin proteolysis. To understand mechanisms underlying Xom-induced proteolysis of b-catenin, we explored the hypothesis that Xom induces b-catenin proteolysis through GSK3-mediated pathway. Using Xenopus A6 cell culture model and transition transfection approach, we found that in comparison to the vector control, Xom expression significantly promotes the expression of GSK3b and the phosphorylation of b-catenin Ser33/37 (Fig. 4A) . We found that the elevated GSK3b protein level is associated with elevated expression of GSK3b mRNA, suggesting that Xom promotes the transcription of GSK3b (Fig. 4B) . To further define the specificity of the findings and the potential functional domains of Xom involved in the process, we tested the effects of Xom deletion mutants on b-catenin Ser33/37 phosphorylation and GSK3b expression. As shown in Fig. 4A , while Xom ND-175 increases the GSK3b expression, promotes phosphorylation of b-catenin Ser33/37 and induces b-catenin proteolysis; XomCD85 failed to promote the expression of GSK3, and the b-catenin Ser33/37 phosphorylation and degradation. These data suggested that Xom Cterminal domain plays an important role in inducing b-catenin proteolysis.
To define whether GSK3 plays a critical role in mediating Xom-induced proteolysis of b-catenin, we developed GSK3-siRNA to down-regulate the expression of GSK3b. The effectiveness of the GSK3-siRNA was first verified in Xenopus A6 cells (Fig. 4C) . The effects of down-regulation of GSK3b on Xom-induced proteolysis of b-catenin was further determined. As shown in Fig. 4D , down-regulation of GSK3 significantly reduces Xom-induced proteolysis of b-catenin, suggesting that GSK3b plays a critical role in mediating Xom-induced proteolysis of b-catenin.
Previous studies showed that b-catenin distributes intracellularly among the membrane, the cytoplasmic, and the nuclear pools [30, 31] . Thus, to further explore the effects of Xom on b-catenin stability, we examined the effects of Xom on b-catenin stability in each individual pools isolated by cell fractionation. Xenopus A6 cells were transfected with plasmid encoding GFPXom or control GFP. To increase the sensitivity of the transfection studies, we sorted out positively transfected cells by FACS. As shown in Fig. 4E , we found that Xom decreased b-catenin levels effectively in the cytoplasmic and nuclear pools. In comparison, Xom exerted little effect on b-catenin in the membrane pools, where the b-catenin is associated with cadherin [32, 33] . Our findings are consistent with the prior notions that binding to cadherin factors stabilize b-catenin and that the nuclear b-catenin level can be regulated by GSK3 [10, 32, 34, 35] . As a control of the experiments, the effect of ectopic Xom expression on cadherin expression level was monitored with RT-PCR. We found that Xom did not alter the expression of cadherin mRNA level (data not shown). The embryos were allowed to develop until stages 6 and 7. Embryonic proteins were then extracted following standard protocol. The levels of GFP-Xom or control GFP and endogenous b-catenin were determined with specific antibodies. b-Tubulin was used as internal loading control. Note, decreased b-catenin protein level in embryos injected with GFP-Xom but not GFP. (E) 34 ng Xom morpholino oligo (XomMo) was injected into each of the two blastomeres at the two-cell stage as previously described [25] . The embryos were allowed to develop until stage 10 and then harvested. The effects of XomMo on the protein levels of endogenous Xom and b-catenin were determined by specific antibodies in subsequent western blot analysis. Note, increased b-catenin but not the control b-tubulin protein in embryos injected with XomMo.
Discussion
A role of ubiquitin-mediated proteolysis in dorsoventral patterning formation was suggested by its involvement in controlling the abundance of both Xom and b-catenin. Our recent findings showed that Xom and b-catenin converge on the common LEF/TCF transcriptional factors for their antagonizing effects on cell fate. In our current studies, we presented biochemical evidence showing that Xom promotes b-catenin proteolysis through promoting GSK3-mediated phosphorylation of b-catenin Ser33/37. Mechanistically, using qRT-PCR methods, we found that Xom promotes the transcription of GSK3 (Fig. 2B) . We further identified that the Xom C-terminal domain is required for inducing GSK3 expression and proteolysis of bcatenin. These results suggest for the first time that, during early embryogenesis, ubiquitin-mediated proteolysis may play a critical regulatory role in balancing the relative abundance of dorsal and ventral cell fate determination factors and maintaining the polarized distribution of Xom and b-catenin during dorsoventral axis formation.
In our current studies, we focused on the role of GSK3 in mediating Xom-induced proteolysis of b-catenin. The findings that Xom promotes the GSK3b expression suggest a potential novel mechanism underlying the ventral enrichment of GSK3b during the establishment of dorsoventral asymmetry [36] . The effect of Xom on b-catenin protein levels was shown in the overexpression experiments. Several factors may account for the limited power of loss-of-function approach in revealing the effects of Xom on bcatenin protein level in vivo. For examples, the Xom morpholino oligos may not have induced sufficient reduction of GSK3 transcription. Also, Xomindependent GSK3 expression may play a role in the proteolysis of b-catenin. The results of our studies raised further questions as of the molecular mechanisms underlying Xom-regulated expression of GSK3b and proteolysis of b-catenin. Recent studies have also revealed GSK3 independent proteolysis of bcatenin by SIAH during the pathogenesis of colon cancer [37] . It remains to be determined whether Xom also involves in GSK3-independent proteolysis of bcatenin.
Signaling events of early embryogenesis have been broadly implicated in clinical medicine. For example, deranged signaling of the Wnt/b-catenin pathways of early embryogenesis has been implicated in malignant transformation in a number of common malignancies, such as colorectal cancer and melanoma [14] . Recently, following the dorsoventral patterning model and the finding of Xom as a LEF/TCF-associated antagonist of the Wnt signaling, we identified VentX, a human Xom homolog, as a novel tumor suppressor and induced p53-independent apoptosis of cancer cells [38] [39] [40] . Mechanistically, we found that, similar to Xom, VentX binds to LEF/TCFs through its homeobox domain and disrupts the interaction between b-catenin and LEF/TCFs [38] . Consistent with its role as a canonical Wnt antagonist, recent studies from our laboratory showed that VentX plays essential role in proliferation and differentiation of hematopoietic and immune cells [41] [42] [43] . As such, further exploration of the regulatory mechanisms of ubiquitin-mediated proteolysis during early embryogenesis is likely to bring novel knowledge that is broadly implicated in immunity, cancer biology, and regenerative medicine.
